Upland Software: 3Q Earnings Snapshot

Associated Press |

AUSTIN, Texas (AP) _ Upland Software Inc. (UPLD) on Thursday reported a loss of $4.3 million in its third quarter.

On a per-share basis, the Austin, Texas-based company said it had a loss of 21 cents. Earnings, adjusted for one-time gains and costs, came to 38 cents per share.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 37 cents per share.

The maker of cloud-based enterprise work-management software posted revenue of $37.1 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $36.5 million.

For the current quarter ending in December, Upland Software said it expects revenue in the range of $41.8 million to $43.8 million.

The company expects full-year revenue in the range of $146.5 million to $148.5 million.

Upland Software shares have increased 48 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $32.09, a climb of 51 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UPLD at https://www.zacks.com/ap/UPLD

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…